2016-12-06
org.kosen.entty.User@33b4d150
김동은(kalilz7)
- 2
중국, 홍콩, 대만에서의 사용되는 leuprolide 용량과 적응증에 대한 정보를 알 수 있을까요?
- 전립선암
- LHRH agonist
- leuprolide
지식의 출발은 질문, 모든 지식의 완성은 답변!
각 분야 한인연구자와 현업 전문가분들의 답변을 기다립니다.
각 분야 한인연구자와 현업 전문가분들의 답변을 기다립니다.
답변 2
-
답변
이경석님의 답변
2016-12-13- 1
진행된 전립선 암 환자한테 근치가 아닌 고통 완화목적으로 사용하는 약물로
생식샘자극호르몬분비호르몬의 길항제라고 합니다.
https://www.drugs.com/pro/leuprolide.html
다음과 같은 논문을 참고할 수 있겠습니다.
Crawford ED1, Moul JW, Sartor O, Shore ND. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. Expert Opin Drug Metab Toxicol. 2015;11(9):1465-74. doi: 10.1517/17425255.2015.1073711.
Suzuki K1, Namiki M2, Fujimoto T3, Takabayashi N3, Kudou K3, Akaza H4. Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan. Jpn J Clin Oncol. 2015 Dec;45(12):1168-74. doi: 10.1093/jjco/hyv149. Epub 2015 Oct 20.
-
답변
김연광님의 답변
2017-06-13- 1
Parenteral
Palliative treatment of advanced prostate cancer
Adult: 1 mg as single daily dose by SC inj. Depot preparations may be given by IM or SC route, dosage and route may differ between different brands and countries. In the UK: As depot preparations: 3.75 mg every mth as single IM/SC inj; or 11.25 mg every 3 mth via SC inj. In the US: As depot preparations: 7.5 mg every mth, or 22.5 mg every 3 mth, or 30 mg every 4 mth via IM/SC inj depending on the preparations; or 45 mg every 6 mth via SC inj.
Parenteral
Endometriosis
Adult: As depot preparations: 3.75 mg every mth given as a single IM/SC inj or 11.25 mg every 3 mth as IM depot Inj. Initiate treatment during the 1st 5 days of menstrual cycle up to 6 mth. May be used with norethindrone acetate 5 mg daily for initial management of endometriosis and for management of recurrence symptoms. Duration of retreatment: Should not exceed one additional 6 mth course.
Parenteral
Uterine fibroids
Adult: As depot preparations: In combination with iron therapy for women with anaemia due to uterine fibroids, 3.75 mg every mth given as a single IM/SC inj or 11.25 mg every 3 mth as IM Inj. Treatment duration: Usually up to 3 mth.
Parenteral
Precocious puberty
Child: As aqueous soln inj: Initial: 50 mcg/kg daily by SC inj, may be titrated upwards by 10 mcg/kg/day if total down-regulation is not achieved. As depot preparations: Initial: 0.3 mg/kg/dose (minimum dose: 7.5 mg) given every 4 wk via IM inj; which equates to children ≤25 kg: 7.5 mg; >25-37.5 kg: 11.25 mg and >37.5 kg: 15 mg given every 4 wk. Maintenance: May titrate dose upwards in steps of 3.75 mg every 4 wk if down-regulation is not achieved. Consider discontinuing therapy before age 11 (females) and age 12 (males).
Parenteral
Preparation for intrauterine surgery
Adult: Endometrial preparation prior to intrauterine surgery: As depot preparations: 3.75 mg as a single inj via IM/SC given 5-6 wk before the procedure; therapy should be initiated during days 3-5 of the menstrual cycle.